ep op dilut data report non-gaap
revenu million data report non-gaap
valu usd unless otherwis note
diversifi expand
view come solid quarter sale guidanc
see potenti addit appreci incywith
low-risk medium-term growth driven jakafi diversification/lif
cycl opportun stem pipelin breadth potenti
bd adjust price target model adjust includ
incorpor itacitinib out-year estim
solid quarter jakafi guidanc reflect continu solid
growth jakafi revenu came slightli our/consensu
est reflect strong growth despit increment
contribut expect inventori normal guidanc
well-receiv our/con prior est
lower end rang compani indic growth
mostli volume-driven albeit increas public payer mix
discount donut hole coverag increas
guidanc includ add revenu gvhd pdufa
strateg initi progress check sg tick
result potenti diversif guidanc
at/slightli consensu line view stabil lead
better oper leverag top line grow though expect
sg uptick higher expect compani prepar
launch gvhd well pemigatinib itacitinib global management
continu emphas high interest acquir late-stag asset
believ would accret exist commerci infrastructur
base previou analys
materi pipelin updat opportun diversif
ahead key year gvhd pdufa jakafi
acut gvhd follow ph iii readout
respect per partner nv earn see note
addit itacitinib global right
studi steroid-na gvhd patient read estimate
near potenti lt sale po addit
continu expand focu dermatolog diversifi around oncolog
-- look year full detail recent report baricitinib ad
data understand potenti rel program
see data topic rux vitiligo model
potenti opportun like take bit time
data jakafi combo pim inhibitor materi
believ could see initi signal later year
key potenti life cycl option least mf lastli
preclin data expect oral inhibitor could help
increas awareness/enthusiasm asset earli could
meaning long-term potenti rel exist revenu base
price prior trade day market close estimate unless otherwis note
bloomberg capit market estim upside/downside/target
base case assum jakafi sale exceed
 long term driven continu growth core market
probabl success new indic
gvhd et assum probability-adjust
out-year baricitinib royalti topic ruxolitinib
pemigatinib itacitinib out-year
probability-adjust annual revenu management pursu
strateg option improv busi effici
price target use dcf discount rate
posit phase data jakafi et gvhd extens
jakafi life cycl next-gen combo better-than-
expect success within earlier-stag pipelin
acquisit big pharma would provid upsid scenario
base dcf analysi would suggest upsid
valu
erod price power jakafi poor perform
earlier-stag pipelin clinic regulatori setback
jakafi combin would lead downsid case
dcf would suggest downsid valu
long-term potenti
jakafi consider
 sale continu beat near-term sale
expect limit downsid risk commerci execut
support strong revenu foundat compani
also believ compani one deepest
cancer-focus pipelin biotech reflect strong drug
discoveri engin busi develop expertis
competit space make difficult pinpoint next first-
in-class blockbust pipelin believ emerg
inflamm franchis potenti greater visibl
jakafi life cycl extens effort like strateg
option improv busi effici could drive valu
posit high opportun jakafi driven growth
exist mf/pv indic long-term opportun et
gvhd strong price power construct partner
good commerci execut deep pipelin cancer
inflammation-focus asset potenti drive long-term
revenu multipl strateg option improv busi
effici unlock valu driven strong rel low-
risk cash flow leverag commerci infrastructur
consider pipelin breadth spend
risk oncolog rheumatolog space
competit farther behind larger compani
approach make import
compani differenti substanti efficacy/safeti
patent expiri time frame life-cycl
extens strategi depend early-stag
pim inhibitor may offer accept
efficacy/safeti alon combo jakafi drug price
potenti catalyst pdufa date jakafi acut
gvhd result reach ph iii
studi full approv acut gvhd file chronic
gvhd result studi itacitinib
treatment-na acut gvhd ph iii data
pemigatinib cholangiocarcinoma
producteventtimelinejakafipdufa date acut acut ph iii studi file full approv acut chronic ph iii studi snda file chronic addit combin strategi pim et trial data ph iii studi atop data ph iii breeze-ad ph ii studi ph iii studi ph iii trial ph iii true-ad trial combo egfr nsclc ph iii treatment-nav acut gvhd data readout ph ii open-label studi low-dos rux combo ph ii cholangiocarcinoma read nda submiss ph ii complet enrol bladder cancer w/ continu ph iii clinic trial cholangiocarcinoma ph iii clinic trial bladder pivot tumor-agnost studi fgf/fgfr mutat solid nda submiss bladder cancer trial readout monotherapi data fl margin zone mantl cell nv cmet nda submiss alk-cmet amplifi ab proof-of-concept data combin checkpoint data combin checkpoint gitr proof-of-concept data combin checkpoint preclin ph pk/pd readout monotherapi msi-high endometri cancer readout monotherapi anal oral ruxolitinibitacitinib exhibit pipelin
drug/target partner/mechan indicationstatusjakafi nv mf pv gvhd etmarket mf pvolumi ra ad slemarket eu japantop ruxolitinibatop dermat vitiligophas phase iiitacitinib uc phase phase iicapmatinib nv cmet nsclcphase iipemigatinib cholangiocarcinoma bladder cancer mpnsphase iiparsaclisib iiepacadostatlung cancer epa pembro phase suppurativaphas combin therapi oncolog monotherapyent phase carcinomaphas sclcphase pim advanc malignanciesphas arg solid tumorsphas gitr solid tumorsphas tumorsphas ab cancerphas ab cancerphas dual inhibitor cancerphas oral inhibitor cancerphas mru cancerent phase ipipelin exhibit incom statement
incom statement thousand except share royalties- net eu revenu royalti probability-adjust revenu probability-adjust ruxolitinib revenu probabilty-adjust revenu probability-adjust pipelin revenu prob-adjust product cost incom net pre-tax benefit incom incom per share outstand share outstand biotechnolog
price target base dcf discount futur cash flow annual
termin growth rate begin jakafi patent expiri probability-weight
potenti favor strateg altern price target support outperform rate
risk rate price target
downsid risk includ greater-than-expect slow jakafi failur extend jakafi life
cycl regulatori setback topic ruxolitinib price pressur limit efficaci signal
within earlier-stag pipelin
biotechnolog compani focus develop commerci
deep pipelin intern discov small molecul drug candid oncolog
inflammatori indic lead product jakafi ruxolitinib inhibitor market
myelofibrosi mf polycythemia vera pv addit acquisit ariad eu
oper add second approv compound portfolio iclusig cml
within inflammatori diseas space incyt advanc compound baricitinib
jak inhibitor out-licens lilli develop drug rheumatoid arthriti
ra indic baricitinib olumi approv ema februari
approv fda drug also explor indic atop
dermat system lupu erythematosu addit compound wholli own
pipelin includ small molecul inhibitor fgfr brd
